The $103 million projects are part of the Texas A&M Center for Innovation in Advanced Development and Manufacturing (CIADM). The facilities were designed to enhance the nation’s ability to respond to emerging infectious diseases, including pandemic influenza and other chemical, biological, radiological, and nuclear threats with vaccines and countermeasures manufactured in the United States. The PIF facility is designed to supply 50 million doses of pandemic influenza vaccine within four months of an outbreak, with the first doses supplied within 12 weeks. PIF. The LVVF was purpose built to house a series of self-contained, modular bioprocessing facilities (MBFs) for flexible manufacturing and processing of small doses of boutique drugs and medical counter-measures. EEA provided the MEP and Clean Utilities Design for the project, including clean spaces, as clean as, ISO-7/Class 10,000 for manufacturing vaccines, combined clean and biological containment laboratory and manufacturing spaces, QC laboratories, and general office spaces.
Beck Group led the design and construction of the project. EEA was a consultant to Beck Architecture for the design of the building.